What an impressive move in $LLY. Oh, well...just add it to the (protracted) list of companies I’ve “watched for too long.” Moving on to another pharma, $PFE has (finally) begun to look like a reasonable buy at these lvls. Initiating, methinks. (No performance promises, as usual.)